You just read:

Intarcia Announces Successful Cardiovascular Safety Results in Phase 3 FREEDOM-CVO Trial for ITCA 650, an Investigational Therapy for Type 2 Diabetes

News provided by

Intarcia Therapeutics, Inc.

May 06, 2016, 10:15 ET